Genematrix P/B

Mitä Genematrix tekee? Genematrix Inc develops RFMP genotyping technology for diagnosing hepatitis B virus (HBV), hepatitis C virus (HCV), and human papillomavirus (HPV) within its pharmaceutical development segment. The company manufactures and sells liver-function examination reagents through its diagnostic medicine segment, while also importing and selling medical equipment and reagents. Customers for these products include healthcare providers and medical facilities requiring viral diagnostics and liver function testing. The pharmaceutical development segment targets laboratories focused on viral infection diagnosis, while the diagnostic medicine segment serves hospitals and clinics needing reagents for liver health assessments. Genematrix Inc's revenue streams come from sales of RFMP-based diagnostic tools for HBV, HCV, and HPV testing, alongside liver-function reagent sales. The company's diagnostic medicine segment generates income through the import and sale of medical equipment and reagents, catering to healthcare institutions. Its pharmaceutical development segment focuses on viral genotyping solutions for medical laboratories, creating a dual revenue model from both diagnostic products and equipment services. The company's products are sold to healthcare institutions requiring viral diagnostics and liver function testing. Pharmaceutical development customers include medical laboratories specializing in HBV, HCV, and HPV testing, while diagnostic medicine customers are hospitals and clinics using liver-function reagents. Genematrix Inc's business model relies on direct sales of its proprietary RFMP technology and imported medical equipment to these specialized healthcare segments without third-party distribution. Genematrix on yksi Eurpooliin suosituimmista yhtiöistä.